XOMA Royalty (NASDAQ:XOMA) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of XOMA Royalty (NASDAQ:XOMA - Free Report) from a buy rating to a hold rating in a report issued on Saturday morning.

A number of other brokerages also recently issued reports on XOMA. HC Wainwright restated a "buy" rating and set a $104.00 price objective on shares of XOMA Royalty in a research report on Wednesday, May 28th. Benchmark started coverage on shares of XOMA Royalty in a research note on Thursday, April 17th. They issued a "buy" rating and a $35.00 price objective on the stock.

XOMA Royalty Stock Up 4.5%

XOMA Royalty stock traded up $1.14 during mid-day trading on Friday, reaching $26.34. The company's stock had a trading volume of 87,618 shares, compared to its average volume of 34,802. The business's 50 day simple moving average is $25.13 and its 200 day simple moving average is $24.24. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $35.00. The company has a debt-to-equity ratio of 1.18, a quick ratio of 5.54 and a current ratio of 5.54. The company has a market capitalization of $315.29 million, a price-to-earnings ratio of -22.90 and a beta of 0.93.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.32. The company had revenue of $15.91 million during the quarter, compared to analysts' expectations of $6.75 million. XOMA Royalty had a negative return on equity of 12.43% and a negative net margin of 13.04%. As a group, research analysts anticipate that XOMA Royalty will post -1.41 earnings per share for the current year.

Insider Activity at XOMA Royalty

In other XOMA Royalty news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the transaction, the insider owned 1,267,545 shares in the company, valued at approximately $34,350,469.50. This represents a 23.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Owen Hughes sold 25,637 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total value of $650,667.06. Following the completion of the sale, the chief executive officer directly owned 62,701 shares in the company, valued at approximately $1,591,351.38. This represents a 29.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 25,178 shares of company stock valued at $636,300. 7.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On XOMA Royalty

Hedge funds have recently added to or reduced their stakes in the stock. Woodline Partners LP increased its position in shares of XOMA Royalty by 63.9% during the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company's stock valued at $4,107,000 after purchasing an additional 60,927 shares during the last quarter. Nuveen LLC purchased a new position in shares of XOMA Royalty in the 1st quarter worth approximately $286,000. CM Management LLC lifted its holdings in shares of XOMA Royalty by 16.4% during the 1st quarter. CM Management LLC now owns 64,000 shares of the biotechnology company's stock valued at $1,276,000 after purchasing an additional 9,000 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in XOMA Royalty by 238.9% in the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company's stock worth $318,000 after acquiring an additional 8,522 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in XOMA Royalty during the 4th quarter valued at approximately $206,000. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.